2024 Session

Budget Amendments - HB30 (Floor Approved)

View Budget Item
View Budget Item amendments

Opioid Abatement Authority

Item 347 #1h

Item 347 #1h

First Year - FY2025 Second Year - FY2026
Health and Human Resources
Opioid Abatement Authority FY2025 $16,419,145 FY2026 $13,964,145 NGF

Page 405, line 46, strike "$66,095,847" and insert "$82,514,992".
Page 405, line 46, strike "$76,107,377" and insert "$90,071,522".

Page 406, after line 10, insert:

"C. The Opioid Abatement Authority shall include as an addendum to its annual executive summary required pursuant to § 2.2-2373, Code of Virginia, an update on prior fiscal year activity related to the Commonwealth Opioid Abatement and Remediation Fund (the Fund), established pursuant to § 2.2-2377, Code of Virginia. Specifically, the addendum shall include an account of any deposits, designations, and expenditures made, along with corresponding performance measures, and other applicable data and information related to the use of Fund settlement proceeds by state agencies.

D.1. Out of appropriations provided in this item, $16,419,145 the first year and $13,964,145 the second year from nongeneral funds is for disbursement from the Commonwealth Opioid Abatement and Remediation Fund for purposes identified as follows:

2. $500,000 the first year and $500,000 the second year to the Department of Behavioral Health and Developmental Services to contract with the Virginia Foundation for Healthy Youth to address the opioid crisis through a marketing campaign and classroom-based programmatic efforts.

3. $2,000,000 the first year to the Department of Criminal Justice Services for deposit in the Jail-Based Substance Use Disorder Treatment and Transition Fund.

4. $5,519,145 the first year and $5,464,145 the second year to the Virginia Department of Health for the purchase and distribution of opioid reversal agents and test kits and for the development of tracking software.

5. $400,000 the first year to the Virginia Department of Health to establish a one-year demonstration project to implement testing for the analysis of fentanyl and norfentanyl in wastewater in up to three geographically diverse localities. The agency shall provide a report on the findings and conclusions of the demonstration project to the Governor, the Chairmen of the House Appropriations and Senate Finance and Appropriations Committees, the Director, Department of Planning and Budget at the conclusion of the demonstration project.

6. a) $8,000,000 the first year and $8,000,000 the second year to the Virginia Department of Health to establish, execute, and administer the Opioid Overdose Reversal Agent Program ("Program"), a manufacturing program for a quality, lowest sustainable cost, opioid overdose reversal agent. The Virginia Department of Health shall coordinate the Program with the Virginia Opioid Abatement Authority. Key objectives of the program shall be: i) providing a long-term, sustainable supply of opioid overdose reversal agent to help combat Virginia's opioid epidemic; ii) providing pricing stability and increase access for this critical life-saving medication; and, iii) leveraging, when possible, existing federal and state investments building the advanced pharmaceutical development and manufacturing CAMPUS in Petersburg.

b) The Program shall contract with the private sector to lead an end-to-end opioid overdose reversal agent nasal spray development program to provide a new FDA-approved generic version resulting in a lower cost product to help drive down state and locality budgets for opioid overdose reversal agent and improve access, quality, and availability through a domestic supply. Funding provided to the contracting entity may be used for: i) investment in research and development activities supporting an opioid overdose reversal agent API, formulation development, manufacturing process qualification and validation, and regulatory approval; and ii) capital expenditures, including custom machinery for assembly of the drug/device combination product and semi-automated packaging. All intellectual property developed by the program would be owned by the private entity and all capital expenditures, including custom equipment, would be owned by the Authority or partner agency."


(This amendment provides nongeneral fund appropriation in each year to designate uses of monies deposited to the Commonwealth Opioid Abatement and Remediation Fund (the Fund). These monies, resulting from settlements, judgements, verdicts, and other court orders relating to consumer protection claims regarding the manufacturing, marketing, distribution, or sale of opioids are to be used for opioid abatement and remediation. Specifically, this portion of settlement monies represent those directed for state appropriation and not subject to allocation by the Opioid Abatement Authority. This amendment also directs the Authority to provide as an addendum to its requisite annual executive summary, an accounting of all activity related to monies deposited, appropriated, and expended from the Fund.)